LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Article: Autophagy.

Reksodiputro, A Harryanto

2007 Volume 39, Issue 4, Page(s) 151–152

MeSH term(s)	Apoptosis ; Autophagy/drug effects ; Autophagy/radiation effects ; Caspase Inhibitors ; Cathepsin B/metabolism ; Cathepsin D/metabolism ; Cytostatic Agents/pharmacology ; Drug Resistance, Neoplasm ; GTP-Binding Proteins ; Humans ; Neoplasm Metastasis ; Neoplasms/metabolism ; Neoplasms/pathology ; Neoplasms/physiopathology ; Organelles ; Transglutaminases/metabolism
Chemical Substances	Caspase Inhibitors ; Cytostatic Agents ; transglutaminase 2 (EC 2.3.2.-) ; Transglutaminases (EC 2.3.2.13) ; Cathepsin B (EC 3.4.22.1) ; Cathepsin D (EC 3.4.23.5) ; GTP-Binding Proteins (EC 3.6.1.-)
Language	English
Publishing date	2007-10
Publishing country	Indonesia
Document type	Comment ; Editorial ; Introductory Journal Article
ZDB-ID	2474707-5
ISSN	2338-2732 ; 0125-9326
ISSN (online)	2338-2732
ISSN	0125-9326
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6834: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role.

Rinaldi, Ikhwan / Reksodiputro, Ary Harryanto / Jusman, Sri Widia / Harahap, Alida / Setiabudy, Rianto / Wanandi, Septelia Inawati / Tambunan, Karmel / Suharti, Catharina

Asian Pacific journal of cancer prevention : APJCP

2019 Volume 20, Issue 12, Page(s) 3689–3695

Abstract: Objective: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp.: Methods: The study was conducted at Dr. ... ...

Abstract	Objective: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. Methods: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital, Jakarta using retrospective cohort design to analyse the association between the duration of HU before IM and its MMR achievement and cross-sectional design to analyse the association between MDA, HIF-1α and P-gp expressions with MMR achievement. Main subjects were chronic-phase CML patients treated by HU prior to IM for ≥ 12 months and HU only. The subjects were divided into four main groups: (1) chronic-phase CML patients treated with HU ≤ 6 months + IM ≥ 12 months and (2) HU > 6 months + IM ≥ 12 months (3) HU only (≤ 6 months), (4) HU only ( >6 months). Subjects were obtained from January 2015 to May 2016. Data were gathered through history taking, physical examination, medical record evaluation, and blood sample analysis. Bivariate analysis was conducted using chi square, independent T-test, and Mann-Whitney according to the variables. Results: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement (RR 1.60; 95%CI 1.29-2.00). MDA level, HIF-1α, P-glycoprotein expression were not associated with MMR achievement but the mean MDA level (0.63±0.31 vs 0.75±0.41 p=0.461) and median P-glycoprotein expressions {16,92 (0,04 - 43,86) vs. 5,15 (0,02-39,64); p=0.311} were found to be higher in patients receiving HU for > 6 months group than in HU ≤ 6 months group consecutively. Conclusion: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement in chronic-phase CML. The study suggested that P-glycoprotein overexpression as the predictor for unsuccessful MMR achievement.
MeSH term(s)	ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism ; Adolescent ; Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Cross-Sectional Studies ; Female ; Humans ; Hydroxyurea/administration & dosage ; Hydroxyurea/therapeutic use ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Imatinib Mesylate/administration & dosage ; Imatinib Mesylate/therapeutic use ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Leukemia, Myeloid, Chronic-Phase/pathology ; Male ; Malondialdehyde/blood ; Middle Aged ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Young Adult
Chemical Substances	ATP Binding Cassette Transporter, Subfamily B, Member 1 ; Antineoplastic Agents ; HIF1A protein, human ; Hypoxia-Inducible Factor 1, alpha Subunit ; Protein Kinase Inhibitors ; Malondialdehyde (4Y8F71G49Q) ; Imatinib Mesylate (8A1O1M485B) ; Hydroxyurea (X6Q56QN5QC)
Language	English
Publishing date	2019-12-01
Publishing country	Thailand
Document type	Journal Article
ZDB-ID	2218955-5
ISSN	2476-762X ; 1513-7368
ISSN (online)	2476-762X
ISSN	1513-7368
DOI	10.31557/APJCP.2019.20.12.3689
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).

British journal of haematology

2020 Volume 189, Issue 2, Page(s) 303–312

Abstract: In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than ... ...

Abstract	In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With ≥48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 ≤ 10% at three months, MMR and molecular response 4·5 (MR
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Benzamides/pharmacology ; Benzamides/therapeutic use ; Female ; Humans ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; Leukemia, Myeloid, Chronic-Phase/complications ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Male ; Middle Aged ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; Treatment Outcome ; Young Adult
Chemical Substances	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide ; Antineoplastic Agents ; Benzamides ; Pyrazines ; Imatinib Mesylate (8A1O1M485B)
Language	English
Publishing date	2020-02-03
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.16381
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Ikhwan Rinaldi / Ary Harryanto Reksodiputro

Jurnal Penyakit Dalam Indonesia, Vol 7, Iss 3, Pp 174-

2020 Volume 180

Abstract: Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis. The complete hematologic ... ...

Abstract	Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis. The complete hematologic response in Indonesia is lower than in the world (74% vs. 95%). Sixty percent of chronic myeloid leukemia patients in Indonesia were administered hydroxyurea before imatinib mesylate. Chronic myeloid leukaemia (CML) patients in Indonesia are younger than in other countries. This study aimed to determine what prognostic factors which affect the complete hematological response of chronic phase CML patients who received imatinib mesylate in Indonesia. Methods. The study was done by retrospective cohort design using the medical records data of chronic myeloid leukemia patients who were treated at Teratai Clinic and hematology clinic RSCM and received imatinib mesylate therapy from January 2004-December 2011. Results. Most of the study subjects were male (61.5%), aged 26-40 years (47.4%), duration of diagnosis <12 months (69.2%), duration of hydroxyurea therapy <6 months (64.1%), hemoglobin concentration <12 g/dl (69.2%), leukocyte count ≥50,000 (48.7%), platelet count 0 – <450,000 (42.3%), spleen size ≥10 cm (55.1%), low Sokal score (42.3%), and achieve a complete hematologic response within 3 months (57.7%). Duration of hydroxyurea therapy <6 months is prognostic factor higher CHR achievement. Conclusions. Clinical and laboratory characteristics CML patients in Indonesia are different than CML patients in the world. Duration of diagnosis until imatinib mesylate administration <12 months, duration of hydroxyurea administration <6 months, and hemoglobin concentration ≤12 g/dl were associated with the achievement of complete hematological response of chronic CML patients in Indonesia. Duration of hydroxyurea administration <6 months was identified as independent factor of achievement of complete hematological response of chronic CML patients in ...
Keywords	complete hematologic response ; imatinib mesylate ; Internal medicine ; RC31-1245
Subject code	610
Language	Indonesian
Publishing date	2020-09-01T00:00:00Z
Publisher	Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Signaling pathways in early onset sporadic breast cancer of patients in Indonesia.

Sutandyo, Noorwati / Suzanna, Evlina / Haryono, Samuel J / Reksodiputro, A Harryanto

Acta medica Indonesiana

2008 Volume 40, Issue 3, Page(s) 139–145

Abstract: Aim: to determine signaling pathways in breast cancers from patients aged 35 years old or younger and patients aged more than 35 years old.: Methods: this was a cross-sectional, comparative study of female breast cancer patients who were recruited ... ...

Abstract	Aim: to determine signaling pathways in breast cancers from patients aged 35 years old or younger and patients aged more than 35 years old. Methods: this was a cross-sectional, comparative study of female breast cancer patients who were recruited and divided into two age groups, i.e. 35 years or younger and more than 35 years old. Specimens were obtained by biopsy or surgical removal of the tumors and were confirmed by histopathological examination. The expression of ER, IGF-1R, Her-2, MAPK, and cyclin D1 were measured using immunohistochemistry. Results: ninety-three patients were recruited from September 2004 to December 2005. Forty-three patients were 35 years or younger. More than 90% of the patients within the two groups showed invasive ductal carcinomas and more than half of these tumors were grade 2. Immunohistochemical staining was successfully done in 90 patients. ER-alpha expression was negative in 33 breast cancers (78.6%) from patients less than 35 years old and 32 cancers (66.7%) of older patients. The expressions of IGF-1R, Her-2, MAPK, and cyclin D1 were positive, respectively in 17 (40.5%), 11 (26.2%), 28 (66.7%), and 7 (16.7%) cancers within the group of patients 35 years old or younger, and, respectively in 18 (37.5%), 11 (22.9%), 37 (77.1%), and 9 (18.8%) of cancers from patients more than 35 years old. Conclusion: there were no statistically significant differences in the expression of any of the biomarkers between the two groups. In all patients, ER was negative in 72.2% cases and MAPK was positive in 76.7% cases. Patients aged 35 years or younger showed similar ER, IGF-1R, Her-2, MAPK, and cyclin D1 expressions compared to cancers from patients more than 35 years old. These were predominantly ER-negative, suggesting that estrogen does not play a dominant role in their growth. The frequent expression of MAPK in these cancers raises the possibility that growth factors play a dominant role in their growth.
MeSH term(s)	Adult ; Age Factors ; Biomarkers, Tumor/analysis ; Breast Neoplasms/epidemiology ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Breast Neoplasms/physiopathology ; Cross-Sectional Studies ; Cyclin D1/analysis ; Female ; Humans ; Immunohistochemistry ; Indonesia/epidemiology ; Mitogen-Activated Protein Kinase Kinases/analysis ; Receptor, ErbB-2/analysis ; Receptor, IGF Type 1/analysis ; Receptors, Estrogen/analysis ; Receptors, Progesterone/analysis ; Signal Transduction ; Time Factors
Chemical Substances	Biomarkers, Tumor ; Receptors, Estrogen ; Receptors, Progesterone ; Cyclin D1 (136601-57-5) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Receptor, IGF Type 1 (EC 2.7.10.1) ; Mitogen-Activated Protein Kinase Kinases (EC 2.7.12.2)
Language	English
Publishing date	2008-07
Publishing country	Indonesia
Document type	Comparative Study ; Journal Article
ZDB-ID	2474707-5
ISSN	2338-2732 ; 0125-9326
ISSN (online)	2338-2732
ISSN	0125-9326
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6834: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cut-off levels based on deviation from standard negative control is better than moderate level based on fixed cut-off for ACA assessed using ELISA for the diagnosis of antiphospholipid syndrome.

Effendy, Shufrie / Tambunan, Karmel L / Reksodiputro, A Harryanto

Acta medica Indonesiana

2005 Volume 37, Issue 1, Page(s) 12–19

Abstract: Aim: To assess the consistency of the standard negative control of IgG and IgM ACA levels within runs and batches of tests, and levels of ACA agreement between those established according to deviation from standard negative control and those established ...

Abstract	Aim: To assess the consistency of the standard negative control of IgG and IgM ACA levels within runs and batches of tests, and levels of ACA agreement between those established according to deviation from standard negative control and those established based on a fixed level cut off. Methods: Serum samples of 148 patients who presented an INR < 0.9 or prothrombin activity of > 130% or aPTT below 0.8 times control or thrombosis with aPTT below 1.2 times control were tested in a 22-time running test to determine IgG and IgM ACA levels using Quanta Lite ACA IgG (HRP) and Quanta Lite ACA IgM (HRP) commercial reagents. Results: Coefficients of variant within runs and batches of standard negative control IgG and IgM ACA levels were 19.30% and 29.17% respectively. Using kappa statistics to determine degree of agreement between cut-off levels by deviation from standard negative control and fixed cut-off level of ACA identified using ELISA, the disagreement in IgM and IgG were k 0.30, and 95% CI of k 0.27 to 0.34 (z = 1.033, p = 0.3015), and k 0.63, and 95% CI of k 0.53 to 0.73 (z = 1.411, p = 0.1584) for cut-off levels based on deviations from standard negative control and fixed cut-off levels respectively. Cut-off levels based on deviation from standard negative control was more sensitive, with a 92% predictive true positive value, compared to a 69% predictive true positive value by fixed cut-off levels of IgM ACA detected using ELISA, and nearly equivalent to IgG ACA, with 84.4% and 87.1% predictive true positive values respectively. Conclusion: Cut-off points based on fixed levels of ACA detected using ELISA cannot be applied, because both IgG and IgM ACA levels of standard negative control were inconsistent among runs and batches. Cut-off points based on the deviation of 3 standard negative control levels for IgG ACA and based on deviations of 2.5 times from standard negative control levels for IgM ACA were better than cut off by fixed levels of ACA in producing true positive results.
MeSH term(s)	Antibodies, Anticardiolipin/blood ; Antiphospholipid Syndrome/blood ; Antiphospholipid Syndrome/diagnosis ; Blood Coagulation Tests ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Predictive Value of Tests ; Reproducibility of Results
Chemical Substances	Antibodies, Anticardiolipin ; Immunoglobulin G ; Immunoglobulin M
Language	English
Publishing date	2005-01
Publishing country	Indonesia
Document type	Journal Article
ZDB-ID	2474707-5
ISSN	2338-2732 ; 0125-9326
ISSN (online)	2338-2732
ISSN	0125-9326
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6834: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia

Wulyo Rajabto / Ary Harryanto Reksodiputro / Ikhwan Rinaldi / Hilman Tadjoedin / Dimas Priantono / Yohana Kusuma Angkasa

Siriraj Medical Journal, Vol 74, Iss

2022 Volume 8

Abstract: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and BCR-ABL fusion oncogene. CML is one of the illnesses that may be treated using Tyrosine Kinase Inhibitors (TKIs), a type of ... ...

Abstract	Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and BCR-ABL fusion oncogene. CML is one of the illnesses that may be treated using Tyrosine Kinase Inhibitors (TKIs), a type of targeted therapy. Since TKIs are the standard of therapy, long-term survival of CML has improved compared to chemotherapy and interferon-alpha. For the first-line treatment for CML, there are four commercially available TKIs that serve as an integral part of the disease management. However, there are many challenges in diagnosing, treating, and monitoring patients with chronic phase CML in Indonesia. This study highlights the epidemiology data of chronic phase CML patients, particularly at Dr. Cipto Mangunkusumo General Hospital, an Indonesian national referral hospital, and how to diagnose, select first-line TKIs, and monitor the response of treatment after TKIs administration.
Keywords	Chronic phase chronic myeloid leukemia ; epidemiology ; diagnosis ; treatment ; monitoring ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2022-08-01T00:00:00Z
Publisher	Mahidol University
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.

Kwak, Jae-Yong / Kim, Sung-Hyun / Oh, Suk Joong / Zang, Dae Young / Kim, Hawk / Kim, Jeong-A / Do, Young Rok / Kim, Hyeoung Joon / Park, Joon Seong / Choi, Chul Won / Lee, Won Sik / Mun, Yeung-Chul / Kong, Jee Hyun / Chung, Joo Seop / Shin, Ho-Jin / Kim, Dae-Young / Park, Jinny / Jung, Chul Won / Bunworasate, Udomsak /

Comia, Narcisa Sonia / Jootar, Saengsuree / Reksodiputro, Arry Harryanto / Caguioa, Priscilla B / Lee, Sung-Eun / Kim, Dong-Wook

Clinical cancer research : an official journal of the American Association for Cancer Research

2017 Volume 23, Issue 23, Page(s) 7180–7188

Abstract: Purpose: ...

Abstract	Purpose:
MeSH term(s)	Adult ; Benzamides/administration & dosage ; Benzamides/adverse effects ; Benzamides/therapeutic use ; Drug Administration Schedule ; Female ; Fusion Proteins, bcr-abl/genetics ; Humans ; Imatinib Mesylate/administration & dosage ; Imatinib Mesylate/adverse effects ; Imatinib Mesylate/therapeutic use ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Leukemia, Myeloid, Chronic-Phase/genetics ; Male ; Middle Aged ; Neutropenia/chemically induced ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyrazines/administration & dosage ; Pyrazines/adverse effects ; Pyrazines/therapeutic use ; Remission Induction ; Thrombocytopenia/chemically induced ; Treatment Outcome
Chemical Substances	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide ; Benzamides ; Protein Kinase Inhibitors ; Pyrazines ; Imatinib Mesylate (8A1O1M485B) ; Fusion Proteins, bcr-abl (EC 2.7.10.2)
Language	English
Publishing date	2017-12-01
Publishing country	United States
Document type	Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-17-0957
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Five Year Survival of Active Multiple Myeloma Patients Based on Durie-Salmon and International Myeloma Working Group 2003 Diagnostic Criteria

Sri Agustini Kurniawati / Ary Harryanto Reksodiputro / Tubagus Djumhana Atmakusuma

Jurnal Penyakit Dalam Indonesia, Vol 7, Iss 3, Pp 161-

2020 Volume 173

Abstract: Introduction. Survival of active multiple myeloma (MM) patients is determined by early diagnosis and various prognostic factors. The development of MM diagnostic criteria from Durie-Salmon (DS) criteria to International Myeloma Working Group (IMWG) 2003 ... ...

Abstract	Introduction. Survival of active multiple myeloma (MM) patients is determined by early diagnosis and various prognostic factors. The development of MM diagnostic criteria from Durie-Salmon (DS) criteria to International Myeloma Working Group (IMWG) 2003 is an attempt to diagnose active MM earlier. However, due to limited resources, these diagnostic criteria cannot be fulfilled consistently in Indonesia. Based on this reason, it is necessary to know the proportion of MM based on DS and IMWG 2003 diagnostic criteria and also their impact on the survival of MM patients in Indonesia. Methods. This was a retrospective cohort study with survival analysis. Subjects were active MM patients in Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital during 2005-2015. Data were presented in Kaplan-Meier survival curve and table with 95% confidence interval (CI). Results. This study involved 102 active MM patients with complete diagnostic data and survival for more than 1 month. As much as 56.9% of patients met DS diagnostic criteria and 72.5% met IMWG 2003 criteria. Median of overall survival (OS) based on DS criteria (77.8 months) was similar with IMWG 2003 criteria. Overall survival in the first, third, and fifth year of MM patients who met DS criteria were 89.9%, 77.5%, and 54.8%, respectively. Meanwhile overall survival in the first, third, and fifth year of MM patients who met IMWG 2003 criteria were 87.5%, 75.6% and 55.9%, respectively. Conclusions. The proportion of active MM patients who met IMWG 2003 diagnostic criteria was higher than those who met DS criteria. Overall survival of active MM patients who meet DS diagnostic criteria is similar with those who met IMWG 2003 criteria.
Keywords	active multiple myeloma ; diagnostic criteria ; durie-salmon ; imwg 2003 ; survival ; Internal medicine ; RC31-1245
Language	Indonesian
Publishing date	2020-09-01T00:00:00Z
Publisher	Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Composite Lymphoma

Noorwati Soetandyo / Ruth Vonky Rebecca / Maria Yunti / Arry Harryanto Reksodiputro

Jurnal Penyakit Dalam Indonesia, Vol 5, Iss 3, Pp 146-

Hodgkin and Non-Hodgkin Lymphoma A Case Report

2018 Volume 149

Abstract: Composite lymphoma (CL) is a rare disease. Composite lymphoma is two or more different type of lymphoma that sequentially or simultaneously occur in one anatomical site. Making a diagnosis of CL is a challenge and there is still no guidelines about the ... ...

Abstract	Composite lymphoma (CL) is a rare disease. Composite lymphoma is two or more different type of lymphoma that sequentially or simultaneously occur in one anatomical site. Making a diagnosis of CL is a challenge and there is still no guidelines about the treatment. This case report is about a 36 y.o female with CL, sequentially consisted of Hodgkin and non-Hodgkin lymphoma.
Keywords	Case report ; Composite ; Lymphoma ; Internal medicine ; RC31-1245
Language	Indonesian
Publishing date	2018-09-01T00:00:00Z
Publisher	Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED